On April 11, 2019 Alligator Bioscience (Nasdaq Stockholm: ATORX), reported that preclinical data for the bispecific CTLA-4 x OX40 antibody ATOR-1015 is published in the Journal of ImmunoTherapy of Cancer (Press release, Alligator Bioscience, APR 11, 2019, View Source [SID1234535140])
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The published data show that ATOR-1015 is localized to the tumor and exhibits anti-tumor effects in several different experimental tumor models, such as bladder, colon and pancreatic cancer. In addition, data show that ATOR-1015 induces a tumor-specific and long-term immunological memory as well as an enhanced anti-tumor response in combination with PD-1 inhibitory therapy.
Data supports the ongoing clinical development of ATOR-1015, currently being evaluated in a Phase I clinical trial (NCT03782467). The results of this study are expected to be compiled during the second half of 2020.
Title: The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
Journal : Journal for ImmunoTherapy of Cancer ( 7 : 103, View Source )
Author: Anne Månsson Kvarnhammar et al.
For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications
Phone: +46 46 540 82 06
E-mail: [email protected]
The information was submitted, through the agency of the above contact person, for publication on April 11, 2019, at 13.30.
About ATOR-1015
ATOR-1015, wholly owned by Alligator, is a bispecific CTLA-4 antibody developed for tumor-directed immunotherapy, with increased capacity for killing regulatory T cells. ATOR-1015 binds to two different immune receptors, the checkpoint receptor CTLA-4 and the co-stimulatory receptor OX40. The immune activation is stronger in those areas where both receptors are highly expressed, as in the tumor area, which can lead to decreased side effects.